Increased soluble TNF receptor-1 and glutathione peroxidase may predict carotid intima media thickness in females with cushing syndrome

Endocrine Practice

Volumn 21, Issue 3, 2015, Pages 286-295

  Shivaprasad, Ks ^a   Kumar, Manoj ^a   Dutta, Deep ^b   Sinha, Bineet ^a   Mondal, Samim ^a   Maisnam, Indira ^c   Mukhopadhyay, Satinath ^a   Chowdhury, Subhankar ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b DR RAM MANOHAR LOHIA HOSPITAL   (India)

^c R G KAR MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FIBRINOGEN; GLUTATHIONE PEROXIDASE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; C REACTIVE PROTEIN; GLUCOSE BLOOD LEVEL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CUSHING DISEASE; DIASTOLIC BLOOD PRESSURE; DOPPLER ULTRASONOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; OVERNIGHT DEXAMETHASONE SUPPRESSION TEST; OXIDATIVE STRESS; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; VASODILATATION; ANALYSIS; BLOOD; CUSHING SYNDROME; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ADULT; ATHEROSCLEROSIS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CAROTID INTIMA-MEDIA THICKNESS; CUSHING SYNDROME; ENDOTHELIUM, VASCULAR; FEMALE; GLUTATHIONE PEROXIDASE; HUMANS; MALE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84982832244     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP14399.OR     Document Type: Article

References (48)

1. Etxabe J, Vazquez JA. Morbidity and mortality in Cushings disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994;40:479-484
2. Doneen AL, Bale BF. Carotid intima-media thickness testing as an asymptomatic cardiovascular disease identifier and method for making therapeutic decisions. Postgrad Med. 2013;125:108-123
3. Colao A, Pivonello R, Spiezia S, et al. Persistence of increased cardiovascular risk in patients with Cushings disease after five years of successful cure. J Clin Endocrinol Metab. 1999;84:2664-2672
4. Faggiano A, Pivonello R, Spiezia S, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushings disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab. 2003;88:2527-2533
5. Ambrosi B, Sartorio A, Pizzocaro A, Passini E, Bottasso B, Federici A. Evaluation of haemostatic and fibrinolytic markers in patients with Cushings syndrome and in patients with adrenal incidentaloma. Exp Clin Endocrinol Diabetes. 2000;108:294-298
6. Inoue T, Matsuoka H, Higashi Y, et al. Flow-mediated vasodilation as a diagnostic modality for vascular failure. Hypertens Res. 2008;31:2105-2113
7. Manresa JM, Zamora A, Toms M, et al. Relationship of classical and non-classical risk factors with genetic variants relevant to coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2006;13:738-744
8. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143
9. Turan B, Pfister K, Diener PA, et al. Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Behcets disease. Scand J Rheumatol. 2008;37:135-141
10. Rojas-Cartagena C, Appleyard CB, Santiago OI, Flores I. Experimental intestinal endometriosis is characterized by increased levels of soluble TNFRSF1B and down regulation of Tnfrsf1a and Tnfrsf1b gene expression. Biol Reprod. 2005;73:1211-1218
11. Owczarek D, Cibor D, Glowacki MK, Ciesla A, Mach P. TNF and soluble forms of TNF receptors 1 and 2 in the serum of patients with Crohns disease and ulcerative colitis. Pol Arch Med Wewn. 2012;122:616-623
12. Mysliwiec J, Kretowski A, Stepien A, Kinalska I. Serum levels of soluble TNFalpha receptors (sTNFR1 and sTNFR2) during corticosteroid treatment in patients with Graves? ophthalmopathy. Immunol Invest. 2004;33:61-68
13. Kristo C, Ueland T, Godang K, Aukrust P, Bollerslev J. Biochemical markers for cardiovascular risk following treatment in endogenous Cushings syndrome. J Endocrinol Invest. 2008;31:400-405
14. Barahona MJ, Sucunza N, Resmini E, et al. Persistent body fat mass and inflammatory marker increases after long-term cure of Cushings syndrome. J Clin Endocrinol Metab. 2009;94:3365-3371
15. Brigelius-Floh? R. Glutathione peroxidases and redoxregulated transcription factors. Biol Chem. 2006;387: 1329-1335
16. Hamanishi T, Furuta H, Kato H, et al. Functional variants in the glutathione peroxidase-1 (GPx-1) gene are associated with increased intima-media thickness of carotid arteries and risk of macrovascular diseases in Japanese type 2 diabetic patients. Diabetes. 2004;53:2455-2460
17. Guignat L, Bertherat J. The diagnosis of Cushings syndrome: an Endocrine Society Clinical Practice Guideline: commentary from a European perspective. Eur J Endocrinol. 2010;163:9-13
18. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, highdensity lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499-508
19. Enomoto M, Adachi H, Hirai Y, et al. LDL-C/HDL-C ratio predicts carotid intima-media thickness progression better than HDL-C or LDL-C alone. J Lipids. 2011;2011:549137
20. Simon A, Chironi, G. The relationship between carotid intima media thickness and coronary atherosclerosis revisited. Eur Heart J. 2007;28:2049-2050
21. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115:1285-1295
22. Thijssen DH, Black MA, Pyke KE, et al. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol. 2011;300:H2-H12
23. Baykan M, Erem C, Gedikli O, et al. Impairment of flowmediated vasodilatation of brachial artery in patients with Cushings syndrome. Endocrine. 2007;31:300-304
24. Akaza I, Yoshimoto T, Tsuchiya K, Hirata Y. Endothelial dysfunction associated with hypercortisolism is reversible in Cushings syndrome. Endocr J. 2010;57:245-252
25. Villa AE, Guzman LA, Chen W, Golomb G, Levy RJ, Topol EJ. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J Clin Invest. 1994;93:1243-1249
26. Libby P, Maroko PR, Bloor CM, Sobel BE, Braunwald E. Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest. 1973;52:599-607
27. Webb SM, Mo D, Lamberts SW, et al. Metabolic, cardiovascular and cerebrovascular outcomes in growth hormone deficient subjects with previous Cushings disease or nonfunctioning pituitary adenoma. J Clin Endocrinol Metab. 2010;95:630-638
28. Boscaro M, Sonino N, Scarda A, et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushings syndrome. J Clin Endocrinol Metab. 2002;87: 3662-3666
29. Malarkey WB, Zvara BJ. Interleukin-1 beta and other cytokines stimulate adrenocorticotropin release from cultured pituitary cells of patients with Cushings disease. J Clin Endocrinol Metab. 1989;69:196-199
30. Blackburn R, Giral P, Bruckert E, et al. Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. Arterioscler Thromb Vasc Biol. 2001;21:1962-1968
31. Wang TJ, Nam BH, Wilson PW, et al. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2002;22:1662-1667
32. Straczkowski M, Kowalska I, Nikolajuk A, et al. Plasma levels of soluble tumor necrosis factor-alpha receptors are related to total and LDL-cholesterol in lean, but not in obese subjects. Cardiovasc Diabetol. 2006;5:14
33. Fernndez-Real JM, Gutirrez C, Ricart W, Castieira MJ, Vendrell J, Richart C. Plasma levels of the soluble fraction of tumor necrosis factor receptors 1 and 2 are independent determinants of plasma cholesterol and LDL-cholesterol concentrations in healthy subjects. Atherosclerosis. 1999;146:321-327
34. Cortez-Cooper M, Meaders E, Stallings J, et al. Soluble TNF and IL-6 receptors: indicators of vascular health in women without cardiovascular disease. Vasc Med. 2013; 18:282-289
35. Elkind MS, Rundek T, Sciacca RR, et al. Interleukin-2 levels are associated with carotid artery intima-media thickness. Atherosclerosis. 2005;180:181-187
36. Yener S, Genc S, Akinci B, et al. Carotid intima media thickness is increased and associated with morning cortisol in subjects with non-functioning adrenal incidentaloma. Endocrine. 2009;35:365-370
37. Toledo-Corral CM, Myers SJ, Li Y, Hodis HN, Goran MI, Weigensberg MJ. Blunted nocturnal cortisol rise is associated with higher carotid artery intima-media thickness (CIMT) in overweight African American and Latino youth. Psychoneuroendocrinology. 2013;38:1658-67
38. Androulakis II, Kaltsas GA, Kollias GE, et al. Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. J Clin Endocrinol Metab. 2014;99:2754-2762
39. Schnabel R, Lubos E, Messow CM, et al. Selenium supplementation improves antioxidant capacity in vitro and in vivo in patients with coronary artery disease The SElenium Therapy in Coronary Artery disease Patients (SETCAP) Study. Am Heart J. 2008;156:1201.e1-11
40. Ziegenhagen MW, Fitschen J, Martinet N, Schlaak M, Muller-Quernheim J. Serum level of soluble tumour factor receptor II (75 kDa) indicates inflammatory activity of sarcoidosis. J Intern Med. 2000;248:33-41
41. Spoettl T, Hausmann M, Klebl F, et al. Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Inflamm Bowel Dis. 2007;13:727-732
42. Lubos E, Loscalzo J, Handy DE. Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal. 2011; 15:1957-1997
43. Karamouzis I, Berardelli R, DAngelo V, et al. Enhanced oxidative stress and platelet activation in patients with Cushings syndrome. Clin Endocrinol (Oxf). 2014 doi: 10.1111/cen.12524 [Epub ahead of print]
44. Obrador E, Valles SL, Benlloch M, et al. Glucocorticoid receptor knockdown decreases the antioxidant protection of B16 melanoma cells: an endocrine system-related mechanism that compromises metastatic cell resistance to vascular endothelium-induced tumor cytotoxicity. PLoS One. 2014;9:e96466
45. Liao H, Li Z, Zheng D, et al. Increased hs-CRP/adiponectin ratio is associated with increase carotid intima-media thickness. Lipids Health Dis. 2014;13:120
46. Abhashi SA, Kryeziu FU, Nazreku FD. Increased carotid intima-media thickness associated with high hs-CRP levels is a predictor of unstable coronary artery disease. Cardiovasc J Afr. 2013;24:270-273
47. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165-2168
48. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-733